Diamyd Medical AB (publ) (FRA:DMN)
Germany · Delayed Price · Currency is EUR | Market Cap | 15.46M -82.3% |
| Revenue (ttm) | 33.96K +98.9% |
| Net Income | -18.80M |
| EPS | -0.15 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.0795 |
| Previous Close | 0.0789 |
| Day's Range | 0.0795 - 0.0795 |
| 52-Week Range | 0.0539 - 1.8000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 24, 2026 |
About Diamyd Medical AB
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to devel... [Read more]
Financial Performance
In fiscal year 2025, Diamyd Medical AB's revenue was 130,000, a change of 0.00% compared to the previous year's 130,000. Losses were -169.78 million, 11.8% more than in 2024.
Financial numbers in SEK Financial StatementsNews
Diamyd Medical AB Transcript: Study result
Interim phase III results for retogatein in type 1 diabetes showed futility, with no efficacy observed in any subgroup, contradicting prior positive data. A thorough investigation is underway, and the trial continues until the root cause is determined. Cash position remains strong at $40 million.
Diamyd Medical AB Press release: Study result
Diamyd Medical AB issued a press release on March 30, 2026, disclosing material business information to investors.
Diamyd Medical AB Slides: Company presentation
Diamyd Medical AB has posted slides in relation to its latest quarterly earnings report, which was published on March 26, 2026.
Diamyd Medical AB Earnings Call Transcript: Q2 2026
Full enrollment in a pivotal phase III trial, $25M in new U.S. financing, and a successful GMP inspection mark major milestones. Additional conditional funding could bring total new cash to $160M, supporting trial completion and pre-commercial activities.
Diamyd Medical AB Quarterly report: Q2 2026
Diamyd Medical AB has published its Q2 2026 quarterly earnings report on March 25, 2026.
Diamyd Medical AB Transcript: Lilla Lördag
A precision medicine approach targeting HLA-defined subgroups in type 1 diabetes is under phase III evaluation, with interim results expected soon. Early data suggest efficacy depends on genetic selection, and regulatory pathways may allow accelerated approval if results are positive.
Diamyd Medical AB Slides: Company presentation
Diamyd Medical AB has posted slides in relation to its latest quarterly earnings report, which was published on February 7, 2026.
Diamyd Medical AB Quarterly report: Q1 2026
Diamyd Medical AB has published its Q1 2026 quarterly earnings report on January 28, 2026.
Diamyd Medical AB Transcript: Status update
Primary efficacy readout for the phase 3 trial has been moved up to 15 months, with interim results expected in March 2026. Early positive data could enable accelerated FDA approval, and durability will still be assessed at 24 months.
Diamyd Medical AB Transcript: Status Update
Type 1 diabetes research is advancing rapidly, with precision medicine and immune tolerance therapies at the forefront. Diamyd Medical’s phase III trial targets genetically defined patients, with an interim readout in March that could accelerate approval. Optimism is high for significant breakthroughs in the next few years.
Diamyd Medical AB Annual report: Q4 2025
Diamyd Medical AB has published its Q4 2025 annual report on October 8, 2025.
Diamyd Medical AB Quarterly report: Q4 2025
Diamyd Medical AB has published its Q4 2025 quarterly earnings report on October 8, 2025.
Diamyd Medical AB Transcript: Investing in Life Science 2025
A precision medicine therapy for Type 1 diabetes is in pivotal phase III trials, targeting patients with a specific genetic profile. Early data show significant preservation of insulin production and potential for accelerated U.S. approval, with strong financial backing and commercialization plans focused on the U.S. and Europe.
Diamyd Medical AB Quarterly report: Q3 2025
Diamyd Medical AB has published its Q3 2025 quarterly earnings report on June 25, 2025.